Thousand Oaks biotech firm Amgen recently licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals Inc., a Johnson & Johnson company. The terms of the agreement include a $50 million upfront payment, the potential for $385 million in success-based milestones and additional sales based milestones and royalties on sales. The agreement provides OMJPI with global rights to the product, but excludes Japan where Amgen has entered into a previous license agreement with respect to the compound. OMJPI and its affiliates will be responsible for future development and commercialization of the compound, a fully human anti-nerve growth factor (NGF) antibody. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.